On August 2, 2022 Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new treatment options, and VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, reported the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition’s Nu.Q technology to support further development of Salarius’ clinical stage drug, seclidemstat (Press release, Salarius Pharmaceuticals, AUG 2, 2022, View Source [SID1234617392]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
"We are delighted to collaborate with Volition and believe its Nu.Q technology may provide valuable biomarker information as we seek to advance the development of seclidemstat in multiple clinical indications," commented David Arthur, Chief Executive Officer of Salarius. "Biomarkers allow for a noninvasive method for determining target engagement and potential drug activity in patients. So, this exciting research collaboration with Volition Rx Limited provides another tool to aid in the development of seclidemstat in clinic."
Gael Forterre, Chief Commercial Officer of Volition, added, "We are excited to be collaborating with Salarius as part of our Nu.Q Discover program which offers biopharma companies and academia access to our state-of-the-art assays for rapid epigenetic profiling. We are looking forward to supporting Salarius in the development and release of their groundbreaking seclidemstat therapy, to directly benefit patients with cancer."